Preliminary responses observed in 6 of 8 evaluable urothelial carcinoma patients (75%), including patients previously treated with enfortumab vedotin and pembrolizumab
Early antitumor activity also observed in squamous NSCLC, SCLC and prostate cancer
kAmkDA2? 4=2DDlQ=686?5$A2?r=2DDQm$wp}vwpx 2?5 wp}v+w~&[ r9:?2k^DA2?m[ kDA2? 4=2DDlQ=686?5$A2?r=2DDQm~4E] ah[ a_aek^DA2?m ^!#}6HDH:C6^ \\ !9C@?E=:?6 q:@A92C>2[ 2 4=:?:42=\DE286 3:@E649?@=@8J 4@>A2?J 56G6=@A:?8 ?6IE\86?6C2E:@? 2?E:3@5J\5CF8 4@?;F82E6D WpsrDX[ E@52J 9:89=:89E65 6?4@FC28:?8 AC6=:>:?2CJ 4=:?:42= C6DF=ED 7@C %y`_` AC6D6?E65 2E E96 tFC@A62? $@4:6EJ 7@C |65:42= ~?4@=@8J Wt$|~X r@?8C6DD a_ae :? |25C:5[ $A2:?[ @? ~4E@36C ab[ a_ae] %96 4@>A2?J 2=D@ 2??@F?465 E96 :?:E:2E:@? @7 !92D6 x3[ H:E9 E96 7:CDE A2E:6?E 5@D65]k^Am
kAm%y`_` :D 2? :?G6DE:82E:@?2= 3:DA64:7:4 psr E2C86E:?8 tvu# 2?5 qf\wb[ :?4@CA@C2E:?8 2 E@A@:D@>6C2D6 x :?9:3:E@C A2J=@25] %96 t$|~ AC6D6?E2E:@? 9:89=:89E65 :ED 6>6C8:?8 D276EJ 2?5 E@=6C23:=:EJ AC@7:=6 2?5 AC6=:>:?2CJ 2?E:EF>@C 24E:G:EJ 24C@DD >F=E:A=6 25G2?465 D@=:5 EF>@CD]k^Am
kAmp>@?8 6:89E C6DA@?D6\6G2=F23=6 A2E:6?ED H:E9 FC@E96=:2= 42C4:?@>2[ D:I 249:6G65 A2CE:2= C6DA@?D6D WfdTX[ :?4=F5:?8 A2E:6?ED AC6G:@FD=J EC62E65 H:E9 6?7@CEF>23 G65@E:? Wt'X 2?5 A6>3C@=:KF>23] !C6=:>:?2CJ 2?E:EF>@C 24E:G:EJ H2D 2=D@ @3D6CG65 :? @E96C D@=:5 EF>@CD[ :?4=F5:?8 DBF2>@FD ?@?\D>2== 46== =F?8 42?46C WDB}$r{rkDEC@?8mXk^DEC@?8m[ D>2== 46== =F?8 42?46C W$r{rX 2?5 AC@DE2E6 42?46C[ DFAA@CE:?8 7FCE96C 4=:?:42= :?G6DE:82E:@? 24C@DD E96D6 :?5:42E:@?D]k^Am
kAm%96 6>6C8:?8 D276EJ 2?5 E@=6C23:=:EJ 7:?5:?8D DFAA@CE 4@?E:?F65 4=:?:42= 6G2=F2E:@?[ H:E9 @?8@:?8 5@D6 6D42=2E:@? 2?5 6IA=@C2E:@? @7 2=E6C?2E:G6 EC62E>6?E D4965F=6D 2:>65 2E @AE:>:K:?8 E96 E96C2A6FE:4 A@E6?E:2= @7 %y`_`]k^Am
kAmQ(6 2C6 6?4@FC2865 3J E96 6>6C8:?8 D276EJ AC@7:=6 2?5 AC6=:>:?2CJ 2?E:EF>@C 24E:G:EJ @7 %y`_`[ A2CE:4F=2C=J :? FC@E96=:2= 42C4:?@>2 2?5 }$r{r[Q D2:5 kDEC@?8m|2CEÃ? $632DE:2? ~=:G@[ |s[ |$4[ r9:67 |65:42= ~77:46C @7 !9C@?E=:?6 q:@A92C>2k^DEC@?8m] Q%96 C6DA@?D6D @3D6CG65 :? A2E:6?ED AC6G:@FD=J EC62E65 H:E9 t' 2?5 A6>3C@=:KF>23 2C6 6DA64:2==J AC@>:D:?8 2D H6 4@?E:?F6 E@ @AE:>:K6 5@D:?8 2?5 EC62E>6?E D4965F=6D]Qk^Am
kA 4=2DDlQAC?E2=QmkDEC@?8mp3@FE %y`_`k^DEC@?8mk^Am
kAm%y`_` :D 2? :?G6DE:82E:@?2= tvu# × qf\wb 3:DA64:7:4 psr :?4@CA@C2E:?8 2 E@A@:D@>6C2D6 x :?9:3:E@C A2J=@25] xE :D 36:?8 6G2=F2E65 :? 2? @?8@:?8 8=@32= !92D6 x DEF5J :? A2E:6?ED H:E9 25G2?465 D@=:5 EF>@CD] %y`_` 92D ?@E 366? 2AAC@G65 3J 2?J C68F=2E@CJ 2FE9@C:EJ[ 2?5 :ED D276EJ 2?5 677:424J 92G6 ?@E 366? 6DE23=:D965]k^Am
kA 4=2DDlQAC?E2=QmkDEC@?8mp3@FE !9C@?E=:?6 q:@A92C>2k^DEC@?8mk^Am
kAm!9C@?E=:?6 q:@A92C>2 :D 2 4=:?:42=\DE286 3:@E649?@=@8J 4@>A2?J 9625BF2CE6C65 :? w2?8K9@F[ r9:?2[ 56G6=@A:?8 ?6IE\86?6C2E:@? psrD 7@C D@=:5 EF>@CD] xED AC@AC:6E2CJ A=2E7@C> 4@>3:?6D 3:DA64:7:4 2?E:3@5J 6?8:?66C:?8[ >F=E:A=6 A2J=@25 >6492?:D>D 2?5 3C2?4965 5F2=\A2J=@25 =:?<6C E649?@=@8J E@ 255C6DD EF>@C 96E6C@86?6:EJ 2?5 EC62E>6?E C6D:DE2?46]k^Am
kAmu@C >@C6 :?7@C>2E:@?[ G:D:E k2 9C67lQ9EEAi^^HHH]A9C@?E=:?63:@]4@>^Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQmHHH]A9C@?E=:?63:@]4@>k^2m]k^Am
kA 4=2DDlQAC?E2=QmkDEC@?8mu@CH2C5\{@@<:?8 $E2E6>6?EDk^DEC@?8mk^Am
kAm%9:D C6=62D6 4@?E2:?D 7@CH2C5\=@@<:?8 DE2E6>6?ED C682C5:?8 %y`_`VD 4=:?:42= 56G6=@A>6?E 2?5 A@E6?E:2= 36?67:ED] p4EF2= C6DF=ED >2J 5:776C >2E6C:2==J 5F6 E@ C:D<D :?96C6?E :? 5CF8 56G6=@A>6?E] !C6=:>:?2CJ 7:?5:?8D 7C@> =:>:E65 A2E:6?E ?F>36CD >2J ?@E AC65:4E @FE4@>6D :? DF3D6BF6?E DEF5:6D] !9C@?E=:?6 F?56CE2<6D ?@ @3=:82E:@? E@ FA52E6 E96D6 DE2E6>6?ED 6I46AE 2D C6BF:C65 3J =2H]k^Am
kA :5lQ!&#{Qmk:>8 E:E=6lQr:D:@?Q H:5E9lQ`aQ 96:89ElQ`aQ 2=ElQr:D:@?Q DC4lQ9EEADi^^6586]AC?6HDH:C6]4@>^4^:>8^72G:4@?]A?8nD?lr}gdafhU2>AjD5la_ae\`_\ahQ ^m ':6H @C:8:?2= 4@?E6?Eik2 :5lQ!#}&#{Q C6=lQ?@7@==@HQ 9C67lQ9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^A9C@?E=:?6\3:@A92C>2\9:89=:89ED\6?4@FC28:?8\AC6=:>:?2CJ\D276EJ\2?5\2?E:EF>@C\24E:G:EJ\@7\E;`_`\AC6D6?E65\2E\6D>@\a_ae\2?5\2??@F?46D\A92D6\:3\:?:E:2E:@?\b_ahacc_g]9E>=Q E2C86ElQ03=2?<Qm9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^A9C@?E=:?6\3:@A92C>2\9:89=:89ED\6?4@FC28:?8\AC6=:>:?2CJ\D276EJ\2?5\2?E:EF>@C\24E:G:EJ\@7\E;`_`\AC6D6?E65\2E\6D>@\a_ae\2?5\2??@F?46D\A92D6\:3\:?:E:2E:@?\b_ahacc_g]9E>=k^2mk^Am
kAm$~&#rt !9C@?E=:?6 q:@A92C>2k^Am
kAmk:>8 2=ElQQ DC4lQ9EEADi^^CE]AC?6HDH:C6]4@>^CE]8:7n}6HDxE6>x5lr}gdafhU2>Aj%C2?D>:DD:@?0x5la_ae`_aha`__!#0}t($0&$!#00000r}gdafhU2>Ajs2E6x5la_ae`_ahQ DEJ=6lQ3@C56Ci_AIj H:5E9i`AIj 96:89Ei`AIjQ ^mk^Am
